What Uniphyllin Continus Treats: Main Uses and Benefits

Uniphyllin Continus is a prolonged-release medication that may be part of symptomatic management for chronic respiratory diseases, helping to provide sustained symptom relief.

Maintenance Therapy and Symptom Control

This medication is commonly used to help with symptoms related to chronic obstructive pulmonary diseases (COPD), including asthma, chronic bronchitis, and emphysema. The core therapeutic domain supports the airways, which helps address the symptoms related to physical discomfort like wheezing and shortness of breath associated with these conditions.

The prolonged-release formulation is relevant for managing symptoms that interfere with daily comfort and endure across the entire day-night cycle, applied when groups of symptoms, including chest tightness, become more noticeable.

“The sustained effect of this therapy is crucial for patients needing continuous support to ease respiratory strain.”

This continuous effect contributes to improved comfort during periods of heightened symptoms and supports the maintenance of more stable air flow.

Adjunctive Uses

This medication may be part of symptomatic management when first-line inhaled treatments do not provide sufficient control, acting as an add-on therapy to provide additional support. It is considered relevant in situations involving certain symptoms linked to organ-specific functional stress, such as the breathing difficulties experienced by adults with left ventricular failure and congestive cardiac failure. This supportive role provides support that helps ease the overall symptom burden in complex cases.

Quick Fact: Relief for Persistent Symptoms
Main Use Context	Long-term control and prophylaxis of bronchospasm.
Primary Symptoms Eased	Wheezing, chest tightness, shortness of breath.
Benefit Focus	Contributes to maintaining stable air flow.
Specialized Use	Adjunctive support for cardiac-related breathing distress.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who can and cannot use Uniphyllin Continus

Scope	Regulatory Status
Populations Allowed	Adults and children aged 6 years and above (and weighing ge 22 kg).
Absolute Contraindications	Hypersensitivity to xanthine derivatives (e.g., Theophylline), Porphyria, and infants under 6 months of age.
Conditional Use (Caution)	Elderly patients, those with hepatic disease, certain cardiac arrhythmias, a history of seizures or convulsions, severe hypertension, or peptic ulcers.
Pregnancy / Lactation	Not administered unless clearly necessary. Clearance is decreased in the third trimester. Use while breastfeeding is restricted to cases where the anticipated maternal benefit outweighs the risk to the child.

The official regulatory documentation for Uniphyllin Continus establishes clear eligibility criteria. The medicine is absolutely contraindicated for specific populations, including individuals with a known allergy to the xanthine class of drugs and those with the disorder porphyria. Furthermore, use is prohibited in infants under six months, and this specific prolonged-release tablet formulation is generally not recommended for children under six years of age. For approved patient groups, use remains conditional for those with pre-existing conditions such as hepatic impairment, severe hypertension, or a history of seizures, where regulatory caution is explicitly advised. Use during the third trimester of pregnancy or while breastfeeding requires careful assessment due to documented physiological changes and drug secretion.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Uniphyllin Continus based on its metabolism and pharmacodynamic effects, primarily requiring monitoring or avoidance of concurrent use with several substance classes.

Documented Pharmacokinetic Interactions

Many interactions are related to changes in the rate at which the body processes the active ingredient, theophylline. Agents documented to increase theophylline plasma concentrations (due to reduced clearance) include specific macrolide and quinolone antibiotics (e.g., Ciprofloxacin, Erythromycin), H2-receptor antagonists (e.g., Cimetidine), certain antifungals, and influenza vaccines. Conversely, products that decrease theophylline levels (due to increased clearance) include antiepileptics (e.g., Phenytoin, Carbamazepine) and the herbal product St John's Wort. Regulatory information mandates that concomitant use with St John's Wort should be avoided.

Documented Pharmacodynamic Interactions

Theophylline can interact with other medicines based on their shared or opposing effects in the body. Concomitant use with beta-adrenergic agonists (e.g., Salbutamol), steroids, or diuretics is documented to potentiate the risk of hypokalaemia (low potassium levels), which requires careful monitoring. Theophylline is also documented to reduce the sedative effects of benzodiazepines and interfere with the action of adenosine receptor agonists (e.g., Regadenoson, Adenosine). Due to a lowered seizure threshold, co-administration with ketamine or esketamine should be avoided.

Substance and Condition-Specific Notes

Lifestyle factors are documented to affect theophylline levels; specifically, smoking tobacco significantly increases the rate of clearance, while excessive caffeine consumption may also be relevant. Age and specific health conditions, such as severe asthma or thyroid disease, are officially noted as factors that may require adjustments to the management of these documented interactions.

Uniphyllin Continus contains the active ingredient theophylline, which exerts its effects primarily through two mechanisms. First, theophylline acts as a non-selective phosphodiesterase (PDE) inhibitor. By inhibiting the PDE enzyme, theophylline increases the intracellular concentration of cyclic adenosine monophosphate (cAMP) within bronchial smooth muscle cells. This mechanistic cascade ultimately leads to relaxation of bronchial smooth muscle cells.

Second, theophylline modulates the effects of adenosine, an endogenous mediator, by acting as a non-selective adenosine receptor antagonist (AR-A). This action modulates downstream signaling effects associated with bronchodilation. The drug also exerts a molecular effect by inhibiting nuclear factor-kappa B (NF-kappaB) translocation, affecting downstream transcription of inflammatory mediators.

Official Instructions for Use

This map synthesizes the established administration guidelines for Uniphyllin Continus prolonged-release tablets.

Instruction	Detail
Route of administration	Oral administration only.
Dosing schedule	The usual adult maintenance dose is often 200 mg twice daily (12-hourly), which may be titrated to 300 mg or 400 mg based on individual response.
Timing in relation to meals	The prolonged-release tablets may be taken with or without food.
Preparation requirements	Tablets must be swallowed whole with water. The tablet must not be broken, crushed, or chewed.
Age-group rules	Paediatric (age ge 6 years) dosing is weight-based (e.g., 9 mg/kg twice daily), calculated on lean bodyweight. Older adults may require a lower, carefully monitored dosage.
Missed-dose rules	If a dose is forgotten but remembered within 4 hours of the scheduled time, it can be taken immediately. The subsequent dose should then be taken at the normal scheduled time.
Special procedural conditions	The dose must be adjusted if the patient starts or stops smoking. Dose adjustments are guided by plasma theophylline concentration monitoring, typically measured 4–6 hours after a dose.

---

Summary of Use Protocol

Administration Method Type: Oral Frequency Pattern: Twice daily (12-hourly) Use-Context Constraints: Administration integrity is required (do not alter the tablet form). Dosing is managed through individualized titration guided by therapeutic plasma concentration monitoring.

The established protocol prioritizes the delivery integrity of the prolonged-release tablet and defines the required twice-daily frequency for consistent drug levels. This structured approach mandates dose individualization based on patient-specific factors, which may involve regular blood testing to ensure appropriate use.

Research Evidence / Overview of Studies

Research into Mechanism of Action

Research has explored the hypothesis that the drug, theophylline, acts as a non-selective phosphodiesterase inhibitor and an adenosine receptor antagonist, including the A2alpha receptor. The compound was evaluated based on this primary hypothesis. Research continues to explore the compound's potential effects in laboratory models, including its relationship with histone deacetylase activation, which is hypothesized to contribute to anti-inflammatory properties at lower concentrations.

---

Clinical Trial Findings

Phase 1 & 2: Evaluation and Dose-Finding

Early-stage research focused on the compound's profile and established its prolonged-release pharmacokinetic profile. Research shows that these initial studies focused on determining the necessary dosing to maintain serum concentrations within the established therapeutic range (typically 5-12 mu g/ mL). Studies also investigated the compound in relation to changes in pain scores and bronchodilation.

Phase 3: Evaluation of Outcomes

Large-scale randomized controlled trials (RCTs) assessed the compound across diverse participant groups, primarily those with asthma and Chronic Obstructive Pulmonary Disease (COPD). One systematic review of RCTs found that, when administered in combination with beta2-agonists to patients with stable COPD, the compound was associated with statistically significant improvements in FEV1 (Forced Expiratory Volume in 1 second) and reported dyspnea scores compared to placebo. Long-term findings regarding sustained therapeutic effects may vary across studies.

---

Research into Co-Administration

Research evaluated potential effects when the compound was co-administered with other treatments. Studies have shown that theophylline clearance can be affected by factors such as age, smoking status, and the simultaneous use of other medications, including certain antibiotics and beta2-agonists. Observations regarding the pharmacokinetic profile in healthy volunteers during limited interaction studies did not indicate major changes in all instances.

Key Studies & References

1. National Heart, Lung, and Blood Institute: Asthma and COPD Guidelines (referencing theophylline's role)

Common questions about Uniphyllin Continus (FAQ)

Q: What is the difference between Uniphyllin Continus and a standard theophylline tablet?

The key difference is the speed at which the medicine is released into the body. Uniphyllin Continus is officially labeled as a prolonged-release tablet, which means it’s specifically formulated to release the active ingredient slowly over many hours. Standard theophylline tablets are generally immediate-release and work quickly.

Q: What is the average duration of action for a single dose of Uniphyllin Continus?

Official product information indicates that this formulation is designed to provide sustained drug levels. This sustained effect is intended to support treatment that aligns with a typical 12-hour period, allowing for continuous therapeutic support.

Q: What should be avoided in the diet while taking this medicine?

Regulatory documents mention that a person’s diet is a factor that can affect how the body processes the drug. Specifically, official warnings note that excessive consumption of caffeine may be relevant to the drug's activity and is noted as a factor that may require monitoring.

Q: What is the meaning of the term 'therapeutic window' for Uniphyllin Continus?

The therapeutic window is the specific range of drug concentration in the bloodstream. This range is associated with an effective level of the medicine with a reduced risk of toxicity. For theophylline, official documents indicate that the optimal range is often targeted between 10 and 15 mu g/ mL.

Q: Why do some people use Uniphyllin Continus instead of inhalers only?

Official documents describe the drug's purpose as supporting the long-term management of chronic conditions. Theophylline provides a consistent, foundational level of support for breathing over 24 hours, which can include both a bronchodilator (airway-widening) effect and specific non-bronchodilator properties, often as an addition to other treatments.

Q: Is there evidence that Uniphyllin Continus works well for night-time asthma symptoms?

The formulation is designed for prolonged-release and is taken in a way that provides a 24-hour therapeutic effect. The purpose of this consistent action is to help control symptoms that can persist throughout the day and night.

Q: What kind of studies support the use of Uniphyllin Continus in children?

Regulatory guidance includes specific, weight-based dosing calculations for children aged 6 years and older. This guidance is derived from pharmacokinetic studies that assess how the drug is processed in this population.

Q: Is Uniphyllin Continus a type of steroid or not?

No. Official documents formally classify Uniphyllin Continus as a methylxanthine derivative. This means it belongs to the class of xanthines and is structurally different from steroid medications.

Q: How long does it usually take to feel the effects after starting Uniphyllin Continus?

Because the tablet is a prolonged-release formulation, the delivery of the active ingredient is controlled. According to official pharmacokinetic information, the process is designed to ensure a gradual and sustained presence of the drug in the bloodstream.

Q: Can Uniphyllin Continus be taken with common over-the-counter pain relievers?

Theophylline is known to interact with many medicines. While specific common over-the-counter (OTC) pain relievers are not listed on all regulatory labels, official guidance emphasizes that a prescriber should always review concurrent use of all medications.

Q: Does Uniphyllin Continus interact with hormonal birth control?

Yes, regulatory information indicates a potential interaction. The co-administration of theophylline with certain contraceptive steroids (hormonal birth control) may cause an increase in the plasma concentration of theophylline, and management of this interaction may require monitoring of the drug's level.

Q: Is the continuous release mechanism the same as extended-release?

The product is officially designated as a 'prolonged-release' formulation. This term, along with others such as 'extended-release' or 'sustained-release,' generally describes dosage forms that are designed to gradually release the drug over a long period to reduce the frequency of dosing.

Q: What happens if a person taking Uniphyllin Continus drinks alcohol?

Official warnings advise caution for patients with a history of chronic alcoholism. Alcohol consumption is noted as a factor that can affect the body's rate of drug processing, potentially leading to an increase in theophylline clearance.

Storage and Disposal Requirements

Uniphyllin Continus tablets must be stored strictly according to regulatory guidelines to ensure product quality and public safety.

Requirement Area	Official Conditions
Temperature	Store at room temperature, typically 20 C to 25 C (68 F to 77 F); do not store above 30 C.
Protection	Keep away from excess heat, moisture, and light.
Container	Keep in the original container, which must be tightly closed and have a child-resistant closure.
Child Safety	Mandatory to keep this medication out of the sight and reach of children.
Disposal	Do not use the tablets after the expiry date. Dispose of unused or expired medicine via drug take-back programs or by mixing with an undesirable substance in a sealed container before placing in household trash. Disposal must adhere to all local, state, and federal regulations.